MY FIRST MILLION · EXTRACTED
Martin Shkreli Reveals How He Made His First $100 Million
6 cold-blooded frameworks from the most controversial investor in America — on pattern recognition, short selling, and building an edge no one else has.
Preview · 3 of 6 tactics
"I don't have an opinion on a stock. I have a thesis. An opinion can change based on emotion. A thesis changes only when the facts change."
Martin Shkreli — pharmaceutical investor, former hedge fund manager, and the internet's most controversial figure — breaks down how he built his initial wealth. Setting aside his legal history, the actual investing frameworks he used are sophisticated and rarely taught. Sam and Shaan get into the mechanics: how he developed his pharmaceutical edge, how he thinks about asymmetric bets, and what most retail investors get catastrophically wrong.
Build an Edge So Deep No One Can See It From the Outside
Shkreli spent years becoming one of the most knowledgeable people in the world on pharmaceutical clinical trials — not just the results, but the design, the statistical methodology, the failure modes, the FDA approval probability math. When he looked at a biotech stock, he wasn't guessing. He was calculating. His edge wasn't access or speed — it was depth. He knew things about specific drug pipelines that most investors, including professionals, simply didn't have the background to know. 'An edge based on information processing depth is sustainable. An edge based on access or tips disappears.'
THE PLAY
Pick one specific domain — one industry, one asset class, one niche — and go 10x deeper than any generalist would. Read everything. Talk to practitioners. Build the framework that lets you see what others miss.
Short Selling as Intelligence Gathering
He used short selling not just as a way to make money, but as a way to force himself to deeply understand a company's weaknesses. Going short requires you to think adversarially — to find the real problems, not just the narrative. That adversarial lens made him a better long investor too. He was always asking: what's the bear case? What does the market have wrong on the upside? Where is the consensus missing something? Most investors only ask the bull case questions. He asked both. 'If you can't articulate the bear case better than the bears, you don't understand the company well enough to be long.'
THE PLAY
For any position you hold or are considering: write the best possible bear case you can construct. If you can't write a compelling one, you haven't done enough research. Find someone who is short the position and understand their argument in detail.
The Market Misprices Binary Events
His specialty: pharmaceutical companies with upcoming FDA decisions. The market systematically misprices binary outcomes because most investors hate binary risk and demand a discount for holding through it. Shkreli used his deep knowledge of clinical trial methodology to assess the actual probability of approval better than the market. When the market priced a drug at 30% approval odds and he calculated 60%, that gap was his trade. The market's discomfort with uncertainty was his profit. 'Every time the market demands a discount for complexity or uncertainty I can analyze, that's an opportunity.'
THE PLAY
Find the category of events or decisions where you have better information processing than the consensus. Look for assets the market discounts specifically because of complexity or uncertainty. That discount, when the probability is actually favorable, is your trade.
Subscribers Only
Unlock the Full Protocol
3 more tactics + Action Plan
TACTIC 04
Thesis-Based Conviction Beats Opinion-Based Trading
TACTIC 05
The Sizing Bet Is Where Most Investors Fail
TACTIC 06
Information Asymmetry Is Temporary — Process Is Permanent
Already subscribed? Log in
Newsletter
Get each new protocol the day it drops
One email per drop. No spam. Unsubscribe anytime.
MY FIRST MILLION · EXTRACTED BY PODEX